The Dreaming Tree Wines, a California wine brand from award-winning winemaker Sean McKenzie and musician Dave Matthews, is proud to announce it has hit $1 Million in charitable donations to environmental organizations The Wilderness Society and Living Lands & Waters in support of reforestation and conservation, a goal it set out to achieve six years ago when the brand was launched.
The Dreaming Tree began with a mission to create sustainably produced and packaged wines, as well as ensure that a portion of proceeds from every bottle purchased benefits organizations on the front lines of environmental conservation by planting trees and protecting the nation’s forests. “The more work we can do like this in towns and cities around the world, the more we can change the outcome of the future of those communities,” says The Dreaming Tree Wines co-conspirator Dave Matthews. “I really feel grateful that there are organizations like The Wilderness Society and Living Lands & Waters that can turn this into a reality.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8127651-dreaming-tree-dave-matthews-wine-environmental-conservation-charity-sustainability/
Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that its first doses of the Fluzone® (Influenza Vaccine) portfolio for the 2017-2018 influenza (“flu”) season have been released by the U.S. Food and Drug Administration (FDA). Sanofi Pasteur has begun distributing initial shipments, representing the first of nearly 70 million total doses of seasonal influenza vaccine manufactured by the company for this upcoming influenza season. Widespread shipment of Fluzone Quadrivalent, Fluzone High-Dose and Fluzone Intradermal Quadrivalent vaccine to health care provider offices, pharmacies and other immunizers will begin in early August to support fall immunization campaigns.
“As we enter the Swiftwater site’s 120th year, it reminds us of our innovation and growth as we came to understand the science of influenza and its impact on human health,” said David P. Greenberg, M.D., Associate Vice President and Regional Medical Head North America, Sanofi Pasteur. “Influenza can be especially severe for the most vulnerable populations, including the elderly, young children and those with compromised immune systems; however, it can also have a serious health impact on otherwise healthy individuals. Sanofi Pasteur is and always has been deeply committed to improving public health by continuously striving to develop new vaccines and on improving existing ones.”
To view the multimedia release go to:
https://www.multivu.com/players/English/8081151-sanofi-pasteur-influenza-vaccine-first-shipment-2017/
Abila, the leading provider of software and services to nonprofits, associations, and government entities, announced today findings from its Nonprofit Finance Study: Managing Growth. This study explores the trends and challenges associated with nonprofit growth, including how organizations plan to grow in the next few years, growth’s impact on risk management and compliance, and the difficulties maintaining organizational culture during growth.
“Approximately 80 percent of surveyed nonprofits say they plan to grow in the next 12 to 18 months,” said Dan Murphy, senior manager of fund accounting strategy for Abila, and study co-author. “However, oftentimes, with growth comes increased complexity. For example, managing risk, maintaining compliance, and retaining an organization’s unique culture becomes more challenging as organizations adopt a wide variety of growth strategies. Those nonprofits that understand and plan for growth now and in the near future will be primed for success.”
To view the multimedia release go to:
https://www.multivu.com/players/English/7858254-abila-nonprofit-finance-study/
Dornier MedTech® America, a global medical device company and the pioneer of Extracorporeal Shock Wave Lithotripsy (ESWL®), has received FDA clearance to market the Delta® III. This is the latest generation of the world’s best-selling and most clinically cited lithotripter, the Delta II.
To view the multimedia release go to:
https://www.multivu.com/players/English/8134451-dornier-medtech-delta-iii-kidney-stone-lithotripter/
